Progesterone
Approved · FDAAlso known as (S)-Progesterone, 17alpha-Progesterone, Bijuva, Corpus Luteum Hormone+21 more
(S)-Progesterone, 17alpha-Progesterone, Bijuva, Corpus Luteum Hormone, Crinone, Eazi-Breed CIDR, Endometrin, Gelbkörperhormon, Lutogynon, Prochieve, Progest, Progesterone (micronized), Progesterone Micronized, Progesterone-IBSA, Prometrium, Synovex C, Synovex S, Progesteron, Progesterona, Progestérone, (S)-4-Pregnene-3,20-dione, (S)-Pregn-4-en-3,20-dione, Pregn-4-ene-3,20-dione, Progesteronum, delta(4)-Pregnene-3,20-dione.
Recent clinical, regulatory, research and industry developments relating to this drug.
Supplemental approval: PROGESTERONE (NDA022057)
Label change: PROGESTERONE (NDA022057)
Hormone Replacement Therapy in Adolescents With Premature Ovarian Insufficiency
PRevention Of Methamphetamine Use Among Postpartum Women Trial (PROMPT)
Metabolic control of luteinizing hormone-responsive ovarian steroidogenesis.
Sex hormones differently regulate lipid metabolism genes in primary human hepatocytes.
Recall (Class II): PROGESTERONE
Diagnostic and therapeutic use of oral micronized progesterone in endocrinology.
Supplemental approval: PROGESTERONE (NDA022057)
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Pharmacology & targets
Known molecular targets and mechanisms supported by curated pharmacology databases.
Regulatory timeline
The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.
Data from the U.S. Food and Drug Administration (U.S. Food and Drug Administration), public domain (CC0).
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes8
Journals, researchers & institutions
- Advanced science (Weinheim, Baden-Wurttemberg, Germany)1
- American journal of obstetrics and gynecology1
- BMC endocrine disorders1
- European journal of endocrinology1
- Journal of affective disorders1
- Journal of applied physiology (Bethesda, Md. : 1985)1
- Conde-Agudelo A2
- Creasy GW2
- Fusey S2
- Hassan SS2
- Romero R2
- Soma-Pillay P2
- Akinbote A1
- Alfirevic Z1
- Aarhus University Hospital1
- Aretaieion Hospital1
- Attikon General Hospital1
- Centre for Immunobiology1
- Centre for Neuroendocrinology and Department of Anatomy1
- Chulalongkorn University and Excellence Center in Diabetes1
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Studied across 6 of the same disease areas as Progesterone in the shared literature.
Studied across 6 of the same disease areas as Progesterone in the shared literature.
Studied across 6 of the same disease areas as Progesterone in the shared literature.
Studied across 4 of the same disease areas as Progesterone in the shared literature.
Studied across 5 of the same disease areas as Progesterone in the shared literature.
Studied across 4 of the same disease areas as Progesterone in the shared literature.
Studied across 2 of the same disease areas as Progesterone in the shared literature.
Studied across 2 of the same disease areas as Progesterone in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials
- Regulatory event sources are credited in the Regulatory Timeline above.